Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project
Patients in our study indicate high willingness to undergo adjuvant therapy, even when facing toxicity. The evaluation of potential side effects and prospects of treatment benefit is highly individual. Therefore, it is important to consider personal patient preferences to make appropriate and shared decision-making.
Authors
- Christine Blome (ORCID: https://orcid.org/0000-0002-1163-1639)
- Katharina C. Kähler (ORCID: https://orcid.org/0000-0001-9953-0893)
- Laura Moysig
- Toni Maria Janke (ORCID: https://orcid.org/0000-0002-9861-9519)
Institutions
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- University Hospital Schleswig-Holstein (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1007/s00432-024-06014-8
- Citations
- 1
- Primary Topic
- Patient-Provider Communication in Healthcare
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Deutsche Forschungsgemeinschaft
- Universitätsklinikum Hamburg-Eppendorf